MINNEAPOLIS--(BUSINESS WIRE)--Reflecting its ongoing commitment to patient safety and clinical research, Medtronic, Inc. (NYSE: MDT), announced today the initiation of the first investigational sites in the United States to participate in PROTECT,1 the company’s global study comparing the Endeavor® and Cypher® drug-eluting stents on key safety metrics, including stent thrombosis – a rare but serious adverse event in which a blood clot forms inside the stent, with the potential to cause heart attack or death.
